Because SGLT2 inhibitors are recommended to patients with DKD or HF due to its cardiorenal protective effects [44], DKD patients in our study might be exposed more to SGLT2 inhibitors than no-DKD patients that can lead to underestimate the risk of DKD on HHF. This evidence concerns the gene SLC5A2 and diabetic kidney disease.